Jul 27, 2017
Boston Scientific Corporation (NYSE: BSX) generated sales of $2.257 billion during the second quarter ended June 30, 2017. This represents growth of 6 percent on a reported basis and 7 percent on...
Jul 5, 2017
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2017 on Thursday, July 27, 2017 at
Jun 27, 2017
Boston Scientific Corporation (NYSE: BSX) is hosting a meeting with the investment community today in New York City to provide an overview of its business and long-term growth strategies. Chairman...
Jun 6, 2017Industry's First MR-Conditional Directional DBS System with Stimulation Visualization
Boston Scientific (NYSE: BSX) has received CE mark for the Vercise™ Gevia™ Deep Brain Stimulation (DBS) System*, a rechargeable, magnetic resonance (MR) conditional device indicated for the...
May 24, 2017Results from Evaluation of Real-World Patients Presented at American Thoracic Society International Conference
Boston Scientific (NYSE: BSX) today announced positive results from the Post Approval Clinical Trial Evaluating Bronchial Thermoplasty (BT) in Severe Persistent Asthma (PAS2) study evaluating...
May 17, 2017
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2017 UBS Global Healthcare Conference on Tuesday, May 23, 2017 in New York City. Susie Lisa, vice president, investor...
May 16, 2017The Boston Scientific LOTUS™ Valve System Demonstrated Superior Efficacy to CoreValve® in Global REPRISE III Trial at One Year
Boston Scientific (NYSE: BSX) today announced positive results from the REPRISE III clinical trial, presented at the annual EuroPCR Scientific Program, in Paris. Data from the study demonstrated...
May 16, 2017Acquisition Expands Company's Structural Heart Portfolio; Increases Offerings for the Treatment of Patients with Valvular Heart Disease
Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Symetis SA, a privately-held Swiss structural heart company focused on minimally-invasive transcatheter...
May 12, 2017Boston Scientific Announces Positive European Registry Results For WATCHMAN™ Left Atrial Appendage Closure DeviceLargest Prospective Study of the WATCHMAN Device Presented as Late-Breaking Trial at Heart Rhythm 2017
Boston Scientific (NYSE: BSX) today announced positive safety and efficacy rates of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device from the EWOLUTION registry presented during a...
May 12, 2017New Data from PLATINUM Diversity Study Presented at SCAI 2017 Provide Important Insights Beyond Traditional Clinically-Reported EndpointsAnalyses Evaluated the Impact of Ethnicity, Gender and Income on Cardiovascular Outcomes
New analyses from the Boston Scientific Corporation (NYSE: BSX) sponsored PLATINUM Diversity study underscore the need for greater understanding of the clinical and nonclinical barriers that can...